Study of vericiguat safety in Japanese chronic heart failure patients
Treatments studied
Part of Heart & circulation clinical trials.
This study checks how safe the medicine vericiguat is for Japanese people with chronic heart failure when used in everyday care. It compares patients who receive vericiguat with patients who continue standard treatments without vericiguat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a patient in Japan (Japanese people only).
- You have chronic heart failure and are already on standard heart failure treatment.
- Your heart failure is at NYHA class II, III, or IV (not class I).
- Your heart ultrasound shows left ventricular ejection fraction (LVEF) under 45%.
- You have not taken vericiguat before (either arm).
- You are not in another interventional (investigational) drug study and you will give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether vericiguat can improve heart function in people with stable heart failure and a reduced pumping ability. It may help if you have not needed hospital or IV treatments for worsening heart failure in the last 6 months.
This study looks at how well Verquvo (vericiguat) works in daily life for Korean adults with chronic heart failure and a weak heart pump. It’s for people whose heart failure has recently gotten worse and who are starting Verquvo for the first time.
This trial tests a new medicine called vericiguat against standard treatments to see if it helps people with worsening heart failure. It may be an option if you have heart failure with a weak heart pump and recently needed more medical help.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
This trial tests a medication called Vericiguat for people with heart failure and a weak heart pump after a past heart attack. It aims to see if the drug can help improve your condition.
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
Hear when a new Chronic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.